The Global Mid-Market Specialist
Alantra, a global investment banking and asset management company focused on the mid-market segment, has acted as sole M&A advisor to Sangamo Therapeutics, a leading development company of technologies for gene-based therapies, on the acquisition of TxCell, a French listed biotech specialized in CAR-Tregs.
The transaction was structured in two parts: an off-market block acquisition from historical shareholders (founder, management, Belsize Asset Management, Auriga, bpifrance and Yorkville) in July 2018, followed by a simplified mandatory tender offer to acquire the shares not yet owned by Sangamo Therapeutics.
Following the tender offer, Sangamo Therapeutics reached the 95% threshold and therefore squeezed-out minority shareholders and delisted the company.
Alantra advised Sangamo Therapeutics in the competitive auction process and acted as presenting and guaranteeing bank for the public tender offer.
The deal represents the sixth listed transaction advised by Alantra in the last two years in France, proving Alantra’s expertise in stock exchange transactions and a great achievement in the development of Alantra in France.
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información ‘aquí’.